Edition:
United States

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

14.05USD
24 Feb 2017
Change (% chg)

$-0.35 (-2.43%)
Prev Close
$14.40
Open
$14.35
Day's High
$14.35
Day's Low
$13.85
Volume
158,776
Avg. Vol
296,751
52-wk High
$37.18
52-wk Low
$11.65

IPXL.OQ

Chart for IPXL.OQ

About

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics... (more)

Overall

Beta: 1.23
Market Cap(Mil.): $1,037.92
Shares Outstanding(Mil.): 73.87
Dividend: --
Yield (%): --

Financials

  IPXL.OQ Industry Sector
P/E (TTM): -- 28.84 29.63
EPS (TTM): -2.54 -- --
ROI: -10.21 13.44 12.96
ROE: -18.73 14.34 14.11

Impax seeks fees from FTC in pay-for-delay lawsuit

Drugmaker Impax Laboratories Inc has asked a federal court to order the Federal Trade Commission to cover some of its legal fees in an antitrust lawsuit the agency dropped and refiled as an administrative proceeding.

Feb 22 2017

FTC settles pay-for-delay lawsuit, files two related complaints

WASHINGTON, Jan 23 The U.S. Federal Trade Commission said on Monday it had settled allegations that Endo Pharmaceuticals violated antitrust law when it agreed to pay rivals Watson Laboratories and Impax to delay introducing generic versions of two painkillers.

Jan 23 2017

CVS slashes price of Impax's EpiPen rival

Drugstore chain CVS Health Corp has cut the price of a generic version of Impax Laboratories Inc's emergency allergy injection, a device similar to Mylan NV's controversial EpiPen.

Jan 12 2017

CVS slashes price of Impax's EpiPen rival

Drugstore chain CVS Health Corp has cut the price of a generic version of Impax Laboratories Inc's emergency allergy injection, a device similar to Mylan NV's controversial EpiPen.

Jan 12 2017

CORRECTED-UPDATE 1-CVS slashes price of Impax's EpiPen rival

Jan 12 Drugstore chain CVS Health Corp has cut the price of a generic version of Impax Laboratories Inc's emergency allergy injection, a device similar to Mylan NV's controversial EpiPen.

Jan 12 2017

CORRECTED-CVS slashes price of Impax's emergency allergy shot

Jan 12 Drugstore chain CVS Health Corp has cut the price of a generic version of Impax Laboratories Inc's emergency allergy injection, a device similar to Mylan NV's controversial Epipen.

Jan 12 2017

BRIEF-Impax appoints J. Kevin Buchi to board

* Impax announces appointment of J. Kevin Buchi to board of directors Source text for Eikon: Further company coverage:

Nov 28 2016

BRIEF-Impax Q3 adjusted EPS $0.37

* Sees total company revenues of approximately $840 million to $855 million (previously $900 million to $940 million)

Nov 09 2016

Endo contract lawsuit against Impax over Opana gets green light

Endo Pharmaceuticals Inc, maker of the opioid painkiller Opana ER, can proceed with a lawsuit accusing Impax Laboratories Inc of breaching a settlement agreement that allowed the latter to sell a generic version of the drug, a federal judge has ruled.

Oct 27 2016

BRIEF-Impax Laboratories announces launch of generic version of Metadate CD

* Announced launch of a generic version of Metadate CD Source text for Eikon: Further company coverage:

Sep 22 2016

More From Around the Web

Earnings vs. Estimates